| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53e211d36ea18a28b99b1bc957d36990
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cd05e5b72804379b07f4a26cd941a6a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bf0ceab440a28b91d70922a4623b1ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cb73270990038a2f07f8e78b51ba4bc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d95949163ddc9c14e1c1cd81c809eaf2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-522 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2007-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b0771d31795d3de3067ff470b0fbe0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f6ef27e7b99656a5e3c5d466a3cc8ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73ac5b3ec2b3168649c2e8a1a726dddd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e80a062e0aac440586ad2c7c8d801be0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a44a84f9d1aaad315094aef97762c04 |
| publicationDate |
2009-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009123492-A1 |
| titleOfInvention |
Generation of new bcg vaccine strains protecting against the establishment of latent mycobacterium tuberculosis infection and reactivation from the latent or persistent state |
| abstract |
A vaccine for treating or preventing the establishment of latent tuberculosis infections is provided. The vaccine comprises a recombinant mycobacterium that overexpresses the transcription factor DosR, at a level sufficient to induce production of the dosR regulon genes or proteins. A host to whom the vaccine is administered mounts an immune response to the dosR regulon proteins and is thus protected from the establishment, persistence or reactivation of latent tuberculosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9506922-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113481232-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114736276-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9173930-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9717782-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8961989-B2 |
| priorityDate |
2007-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |